Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Core Insights - AnaptysBio, Inc. is focused on developing innovative immunology therapeutics, with key upcoming clinical data releases for its drug candidates ANB032 and rosnilimab in atopic dermatitis and rheumatoid arthritis, respectively [1][2][3][4] Clinical Development Updates - Top-line Phase 2b data for ANB032, a BTLA agonist, is expected in December 2024, with approximately 200 patients enrolled in a placebo-controlled trial [3] - Top-line Phase 2b data for rosnilimab, a PD-1 agonist, is anticipated in February 2025, following the completion of enrollment of around 420 patients [4] - A Phase 1 trial for ANB033, an anti-CD122 antagonist, has been initiated in healthy volunteers, with further indications expected in 2025 [5] Financial Performance - As of September 30, 2024, the company reported cash and investments totaling $458.0 million, an increase from$417.9 million at the end of 2023, primarily due to a $100.0 million offering and$50.0 million from royalty monetization [7] - Collaboration revenue for Q3 2024 was $30.0 million, significantly up from$3.3 million in Q3 2023, driven by a commercial milestone from Jemperli sales [7] - Research and development expenses rose to $42.2 million for Q3 2024, compared to$30.9 million in Q3 2023, reflecting increased development costs for key drug candidates [7] Pipeline Overview - The company has multiple programs in clinical development, including ANB032 for atopic dermatitis, rosnilimab for rheumatoid arthritis and ulcerative colitis, and ANB101, a BDCA2 modulator, which is set to enter Phase 1 trials in Q1 2025 [9] - AnaptysBio also has legacy cytokine antagonist programs available for out-licensing, including imsidolimab, which has completed Phase 3 trials for generalized pustular psoriasis [5][9]